Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Harris, KA; Small, EJ
   Hormonal treatment for prostate cancer
   EXPERT OPINION ON INVESTIGATIONAL DRUGS
   
   K.A. Harris e E.J. Small, "Hormonal treatment for prostate cancer", EXPERT OP I, 10(3), 2001, pp. 493-510
2. Small, EJ; Harris, KA; Frohlich, MW; Bok, R
   The UCSF advanced prostate cancer program
   UROLOGIC ONCOLOGY
   
   E.J. Small et al., "The UCSF advanced prostate cancer program", UROL ONCOL, 6(5), 2001, pp. 197-201
3. George, DJ; Halabi, S; Shepard, TF; Vogelzang, NJ; Hayes, DF; Small, EJ; Kantoff, PW
   Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on cancer andleukemia group B 9480
   CLINICAL CANCER RESEARCH
   
   D.J. George et al., "Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on cancer andleukemia group B 9480", CLIN CANC R, 7(7), 2001, pp. 1932-1936
4. Ko, YJ; Small, EJ; Kabbinavar, F; Chachoua, A; Taneja, S; Reese, D; DePaoli, A; Hannah, A; Balk, SP; Bubley, GJ
   A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer
   CLINICAL CANCER RESEARCH
   
   Y.J. Ko et al., "A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer", CLIN CANC R, 7(4), 2001, pp. 800-805
5. Mehta, R; Kyshtoobayeva, A; Kurosaki, T; Small, EJ; Kim, H; Stroup, R; McLaren, CE; Li, KT; Fruehauf, JP
   Independent association of angiogenesis index with outcome in prostate cancer
   CLINICAL CANCER RESEARCH
   
   R. Mehta et al., "Independent association of angiogenesis index with outcome in prostate cancer", CLIN CANC R, 7(1), 2001, pp. 81-88
6. Rini, BI; Small, EJ
   An update on prostate cancer
   CURRENT OPINION IN ONCOLOGY
   
   B.I. Rini e E.J. Small, "An update on prostate cancer", CURR OPIN O, 13(3), 2001, pp. 204-211
7. Small, EJ
   Docetaxel in prostate cancer
   ANTI-CANCER DRUGS
   
   E.J. Small, "Docetaxel in prostate cancer", ANTI-CANC D, 12, 2001, pp. S17-S20
8. Savarese, DM; Halabi, S; Hars, V; Akerley, WL; Taplin, ME; Godley, PA; Hussain, A; Small, EJ; Vogelzang, NJ
   Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780
   JOURNAL OF CLINICAL ONCOLOGY
   
   D.M. Savarese et al., "Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780", J CL ONCOL, 19(9), 2001, pp. 2509-2516
9. Small, EJ; McMillan, A; Meyer, M; Chen, L; Slichenmyer, WJ; Lenehan, PF; Eisenberger, M
   Serum prostate-specific antigen decline as a marker of clinical outcome inhormone-refractory prostate cancer patients: Association with progression-free survival, pain end points, and survival
   JOURNAL OF CLINICAL ONCOLOGY
   
   E.J. Small et al., "Serum prostate-specific antigen decline as a marker of clinical outcome inhormone-refractory prostate cancer patients: Association with progression-free survival, pain end points, and survival", J CL ONCOL, 19(5), 2001, pp. 1304-1311
10. Kantoff, PW; Halabi, S; Farmer, DA; Hayes, DF; Vogelzang, NA; Small, EJ
    Prognostic significance of reverse transcriptase polymerase chain reactionfor prostate-specific antigen in men with hormone-refractory prostate cancer
    JOURNAL OF CLINICAL ONCOLOGY
    
    P.W. Kantoff et al., "Prognostic significance of reverse transcriptase polymerase chain reactionfor prostate-specific antigen in men with hormone-refractory prostate cancer", J CL ONCOL, 19(12), 2001, pp. 3025-3028
11. Kelly, WK; Curley, T; Slovin, S; Heller, G; McCaffrey, J; Bajorin, D; Ciolino, A; Regan, K; Schwartz, M; Kantoff, P; George, D; Oh, W; Smith, M; Kaufman, D; Small, EJ; Schwartz, L; Larson, S; Tong, W; Scher, H
    Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer
    JOURNAL OF CLINICAL ONCOLOGY
    
    W.K. Kelly et al., "Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer", J CL ONCOL, 19(1), 2001, pp. 44-53
12. Small, EJ; Bok, R; Reese, DM; Sudilovsky, D; Frohlich, M
    Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer
    SEMINARS IN ONCOLOGY
    
    E.J. Small et al., "Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer", SEMIN ONCOL, 28(4), 2001, pp. 71-76
13. Grossfeld, GD; Small, EJ; Lubeck, DP; Latini, D; Broering, JM; Carroll, PR
    Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy
    UROLOGY
    
    G.D. Grossfeld et al., "Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy", UROLOGY, 58(2A), 2001, pp. 56-64
14. Grossfeld, GD; Chaudhary, UB; Reese, DM; Carroll, PR; Small, EJ
    Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer
    UROLOGY
    
    G.D. Grossfeld et al., "Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer", UROLOGY, 58(2), 2001, pp. 240-245
15. Bok, RA; Halabi, S; Fei, DT; Rodriquez, CR; Hayes, DF; Vogelzang, NJ; Kantoff, P; Shuman, MA; Small, EJ
    Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study
    CANCER RESEARCH
    
    R.A. Bok et al., "Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study", CANCER RES, 61(6), 2001, pp. 2533-2536
16. Reese, DM; Small, EJ; Magrane, G; Waldman, FM; Chew, K; Sudilovsky, D
    HER2 protein expression and gene amplification in androgen-independent prostate cancer
    AJCP. American journal of clinical pathology
    
    D.M. Reese et al., "HER2 protein expression and gene amplification in androgen-independent prostate cancer", AM J CLIN P, 116(2), 2001, pp. 234-239
17. Small, EJ; Reese, DM
    An update on prostate cancer research
    CURRENT OPINION IN ONCOLOGY
    
    E.J. Small e D.M. Reese, "An update on prostate cancer research", CURR OPIN O, 12(3), 2000, pp. 265-272
18. Small, EJ
    Management of advanced/metastatic prostate cancer: 2000 update - The Hussain/Dawson article reviewed
    ONCOLOGY-NEW YORK
    
    E.J. Small, "Management of advanced/metastatic prostate cancer: 2000 update - The Hussain/Dawson article reviewed", ONCOLOGY-NY, 14(12), 2000, pp. 1692-1693
19. Small, EJ; Meyer, M; Marshall, ME; Reyno, LM; Meyers, FJ; Natale, RB; Lenehan, PF; Chen, L; Slichenmyer, WJ; Eisenberger, M
    Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
    JOURNAL OF CLINICAL ONCOLOGY
    
    E.J. Small et al., "Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone", J CL ONCOL, 18(7), 2000, pp. 1440-1450
20. Hussain, M; Fisher, EI; Petrylak, DP; O'Connor, J; Wood, DP; Small, EJ; Eisenberger, MA; Crawford, ED
    Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A southwest oncology group study
    JOURNAL OF CLINICAL ONCOLOGY
    
    M. Hussain et al., "Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A southwest oncology group study", J CL ONCOL, 18(5), 2000, pp. 1043-1049
21. Small, EJ; Fratesi, P; Reese, DM; Strang, G; Laus, R; Peshwa, MV; Valone, FH
    Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
    JOURNAL OF CLINICAL ONCOLOGY
    
    E.J. Small et al., "Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells", J CL ONCOL, 18(23), 2000, pp. 3894-3903
22. Small, EJ; Frohlich, MW; Bok, R; Shinohara, K; Grossfeld, G; Rozenblat, Z; Kelly, WK; Corry, M; Reese, DM
    Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer
    JOURNAL OF CLINICAL ONCOLOGY
    
    E.J. Small et al., "Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer", J CL ONCOL, 18(21), 2000, pp. 3595-3603
23. Roach, M; Reese, D; Weinberg, V; Small, EJ; Carroll, PR
    Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer?
    JOURNAL OF CLINICAL ONCOLOGY
    
    M. Roach et al., "Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer?", J CL ONCOL, 18(2), 2000, pp. 448-449
24. Small, EJ; Lew, D; Redman, BG; Petrylak, DP; Hammond, N; Gross, HM; Eastham, JA; Crawford, ED
    Southwest oncology group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: The importance of survival as a clinical trialend point
    JOURNAL OF CLINICAL ONCOLOGY
    
    E.J. Small et al., "Southwest oncology group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: The importance of survival as a clinical trialend point", J CL ONCOL, 18(13), 2000, pp. 2537-2544
25. Small, EJ; Figlin, R; Petrylak, D; Vaughn, DJ; Sartor, O; Horak, I; Pincus, R; Kremer, A; Bowden, C
    A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma
    INVESTIGATIONAL NEW DRUGS
    
    E.J. Small et al., "A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma", INV NEW DR, 18(2), 2000, pp. 193-197
26. Tigrani, VS; Reese, DM; Small, EJ; Presti, JC; Carroll, PR
    Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: A retrospective analysis
    UROLOGY
    
    V.S. Tigrani et al., "Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: A retrospective analysis", UROLOGY, 55(1), 2000, pp. 36-40
27. Small, EJ; Reese, DM
    New treatment strategies in advanced prostate cancer
    RADIOLOGIC CLINICS OF NORTH AMERICA
    
    E.J. Small e D.M. Reese, "New treatment strategies in advanced prostate cancer", RAD CLIN NA, 38(1), 2000, pp. 203
28. Grossfeld, GD; Tigrani, VS; Nudell, D; Roach, M; Weinberg, VK; Presti, JC; Small, EJ; Carroll, PR
    Management of a positive surgical margin after radical prostatectomy: Decision analysis
    JOURNAL OF UROLOGY
    
    G.D. Grossfeld et al., "Management of a positive surgical margin after radical prostatectomy: Decision analysis", J UROL, 164(1), 2000, pp. 93-99
29. Grossfeld, GD; Tigrani, VS; Nudell, D; Roach, M; Weinberg, VK; Presti, JC; Small, EJ; Carroll, PR
    Management of a positive surgical margin after radical prostatectomy: Decision analysis - Reply
    JOURNAL OF UROLOGY
    
    G.D. Grossfeld et al., "Management of a positive surgical margin after radical prostatectomy: Decision analysis - Reply", J UROL, 164(1), 2000, pp. 100-100
30. Reese, DM; Corry, M; Small, EJ
    Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma
    CANCER
    
    D.M. Reese et al., "Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma", CANCER, 88(6), 2000, pp. 1310-1316
31. Dawson, NA; Conaway, M; Halabi, S; Winer, EP; Small, EJ; Lake, D; Vogelzang, NJ
    A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma - Cancer and leukemia group B study 9181
    CANCER
    
    N.A. Dawson et al., "A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma - Cancer and leukemia group B study 9181", CANCER, 88(4), 2000, pp. 825-834
32. Small, EJ; Reese, DM; Um, B; Whisenant, S; Dixon, SC; Figg, WD
    Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor
    CLINICAL CANCER RESEARCH
    
    E.J. Small et al., "Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor", CLIN CANC R, 5(7), 1999, pp. 1738-1744
33. Bubley, GJ; Carducci, M; Dahut, W; Dawson, N; Daliani, D; Eisenberger, M; Figg, WD; Freidlin, B; Halabi, S; Hudes, G; Hussain, M; Kaplan, R; Myers, C; Oh, W; Petrylak, DP; Reed, E; Roth, B; Sartor, O; Scher, H; Simons, J; Sinibaldi, V; Small, EJ; Smith, MR; Trump, DL; Vollmer, R; Wilding, G
    Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group
    JOURNAL OF CLINICAL ONCOLOGY
    
    G.J. Bubley et al., "Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group", J CL ONCOL, 17(11), 1999, pp. 3461-3467
34. Bok, AB; Small, EJ
    The treatment of advanced prostate cancer with ketoconazole - Safety issues
    DRUG SAFETY
    
    A.B. Bok e E.J. Small, "The treatment of advanced prostate cancer with ketoconazole - Safety issues", DRUG SAFETY, 20(5), 1999, pp. 451-458
35. Reese, DM; Small, EJ
    Secondary hormonal manipulations in hormone refractory prostate cancer
    UROLOGIC CLINICS OF NORTH AMERICA
    
    D.M. Reese e E.J. Small, "Secondary hormonal manipulations in hormone refractory prostate cancer", UROL CLIN N, 26(2), 1999, pp. 311
36. Small, EJ; Reese, DM; Vogelzang, NJ
    Hormone-refractory prostate cancer: An evolving standard of care
    SEMINARS IN ONCOLOGY
    
    E.J. Small et al., "Hormone-refractory prostate cancer: An evolving standard of care", SEMIN ONCOL, 26(5), 1999, pp. 61-67
37. Small, EJ
    PC-SPES in prostate cancer
    NEW ENGLAND JOURNAL OF MEDICINE
    
    E.J. Small, "PC-SPES in prostate cancer", N ENG J MED, 340(7), 1999, pp. 566-567
38. Taplin, ME; Bubley, GJ; Ko, YJ; Small, EJ; Upton, M; Rajeshkumar, B; Balk, SP
    Selection for androgen receptor mutations in prostate cancers treated withandrogen antagonist
    CANCER RESEARCH
    
    M.E. Taplin et al., "Selection for androgen receptor mutations in prostate cancers treated withandrogen antagonist", CANCER RES, 59(11), 1999, pp. 2511-2515
39. Kashani-Sabet, M; Sagebiel, RW; Collins, HE; Glassberg, AB; Allen, RE; Leong, SPL; Small, EJ
    Outpatient combination chemoimmunotherapy for patients with metastatic melanoma - Results of a phase I/II trial
    CANCER
    
    M. Kashani-Sabet et al., "Outpatient combination chemoimmunotherapy for patients with metastatic melanoma - Results of a phase I/II trial", CANCER, 86(10), 1999, pp. 2160-2165
40. Coakley, FV; Hricak, H; Presti, JC; Small, EJ
    Diffuse retroperitoneal amyloidosis due to renal cell carcinoma
    BRITISH JOURNAL OF RADIOLOGY
    
    F.V. Coakley et al., "Diffuse retroperitoneal amyloidosis due to renal cell carcinoma", BR J RADIOL, 72(856), 1999, pp. 412-413
41. SMALL EJ
    PROSTATE-CANCER - INCIDENCE, MANAGEMENT AND OUTCOMES
    Drugs & aging
    
    E.J. Small, "PROSTATE-CANCER - INCIDENCE, MANAGEMENT AND OUTCOMES", Drugs & aging, 13(1), 1998, pp. 71-81
42. SMALL EJ; WEISS GR; MALIK UK; WALTHER PJ; JOHNSON D; WILDING G; KUZEL T; BEJAMONDE A; PATON V
    THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA PATIENTS WITH RECOMBINANT HUMAN GAMMA-INTERFERON
    The cancer journal from Scientific American
    
    E.J. Small et al., "THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA PATIENTS WITH RECOMBINANT HUMAN GAMMA-INTERFERON", The cancer journal from Scientific American, 4(3), 1998, pp. 162-167
43. SMALL EJ; FIPPIN LJ; WHISENANT SP
    PYRAZOLOACRIDINE FOR THE TREATMENT OF HORMONE-REFRACTORY PROSTATE-CANCER
    Cancer investigation
    
    E.J. Small et al., "PYRAZOLOACRIDINE FOR THE TREATMENT OF HORMONE-REFRACTORY PROSTATE-CANCER", Cancer investigation, 16(7), 1998, pp. 456-461
44. FROHLICH MW; SMALL EJ
    STAGE-II NONSEMINOMATOUS TESTIS CANCER - THE ROLES OF PRIMARY AND ADJUVANT CHEMOTHERAPY
    Urologic clinics of North America
    
    M.W. Frohlich e E.J. Small, "STAGE-II NONSEMINOMATOUS TESTIS CANCER - THE ROLES OF PRIMARY AND ADJUVANT CHEMOTHERAPY", Urologic clinics of North America, 25(3), 1998, pp. 451
45. GROSSFELD GD; SMALL EJ
    LONG-TERM SIDE-EFFECTS OF TREATMENT FOR TESTIS CANCER
    Urologic clinics of North America
    
    G.D. Grossfeld e E.J. Small, "LONG-TERM SIDE-EFFECTS OF TREATMENT FOR TESTIS CANCER", Urologic clinics of North America, 25(3), 1998, pp. 503
46. GROSSFELD GD; SMALL EJ; CARROLL PR
    INTERMITTENT ANDROGEN DEPRIVATION FOR CLINICALLY LOCALIZED PROSTATE-CANCER - INITIAL EXPERIENCE
    Urology
    
    G.D. Grossfeld et al., "INTERMITTENT ANDROGEN DEPRIVATION FOR CLINICALLY LOCALIZED PROSTATE-CANCER - INITIAL EXPERIENCE", Urology, 51(1), 1998, pp. 137-144
47. SHADAN S; BHATT A; CHALLA S; PRICE D; SMALL EJ; HAWKINS RA
    THE UTILITY OF PROSTASCINT SCINTIGRAPHY FOR PROSTATE-CANCER METASTASIS OR RECURRENCE
    Radiology
    
    S. Shadan et al., "THE UTILITY OF PROSTASCINT SCINTIGRAPHY FOR PROSTATE-CANCER METASTASIS OR RECURRENCE", Radiology, 209P, 1998, pp. 518-518
48. SMALL EJ; WHISENANT S; GUILD C; FIGG WD
    IMMUNOLOGICAL THERAPY OF PROSTATE-CANCER WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF)
    The Journal of urology
    
    E.J. Small et al., "IMMUNOLOGICAL THERAPY OF PROSTATE-CANCER WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF)", The Journal of urology, 159(5), 1998, pp. 1293-1293
49. SMALL EJ; VOGELZANG NJ
    2ND-LINE HORMONAL-THERAPY FOR ADVANCED PROSTATE-CANCER - A SHIFTING PARADIGM
    Journal of clinical oncology
    
    E.J. Small e N.J. Vogelzang, "2ND-LINE HORMONAL-THERAPY FOR ADVANCED PROSTATE-CANCER - A SHIFTING PARADIGM", Journal of clinical oncology, 15(1), 1997, pp. 382-388
50. SMALL EJ
    CHARACTERIZATION OF PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATIC-CARCINOMA WHOSE SERUM PROSTATE-SPECIFIC ANTIGEN DECREASED FOLLOWING FLUTAMIDE WITHDRAWAL
    The Journal of urology
    
    E.J. Small, "CHARACTERIZATION OF PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATIC-CARCINOMA WHOSE SERUM PROSTATE-SPECIFIC ANTIGEN DECREASED FOLLOWING FLUTAMIDE WITHDRAWAL", The Journal of urology, 158(2), 1997, pp. 552-552
51. SCHELLHAMMER PF; VENNER P; HAAS GP; SMALL EJ; NIEH PT; SEABAUGH DR; PATTERSON AL; KLEIN E; WAJSMAN Z; FURR B; CHEN YS; KOLVENBAG GJCM
    PROSTATE-SPECIFIC ANTIGEN DECREASES AFTER WITHDRAWAL OF ANTIANDROGEN THERAPY WITH BICALUTAMIDE OR FLUTAMIDE IN PATIENTS RECEIVING COMBINED ANDROGEN BLOCKADE
    The Journal of urology
    
    P.F. Schellhammer et al., "PROSTATE-SPECIFIC ANTIGEN DECREASES AFTER WITHDRAWAL OF ANTIANDROGEN THERAPY WITH BICALUTAMIDE OR FLUTAMIDE IN PATIENTS RECEIVING COMBINED ANDROGEN BLOCKADE", The Journal of urology, 157(5), 1997, pp. 1731-1735
52. SMALL EJ; BARON AD; FIPPIN L; APODACA D
    KETOCONAZOLE RETAINS ACTIVITY IN ADVANCED PROSTATE-CANCER PATIENTS WITH PROGRESSION DESPITE FLUTAMIDE WITHDRAWAL
    The Journal of urology
    
    E.J. Small et al., "KETOCONAZOLE RETAINS ACTIVITY IN ADVANCED PROSTATE-CANCER PATIENTS WITH PROGRESSION DESPITE FLUTAMIDE WITHDRAWAL", The Journal of urology, 157(4), 1997, pp. 1204-1207
53. SMALL EJ; BARON A; BOK R
    SIMULTANEOUS ANTIANDROGEN WITHDRAWAL AND TREATMENT WITH KETOCONAZOLE AND HYDROCORTISONE IN PATIENTS WITH ADVANCED PROSTATE CARCINOMA
    Cancer
    
    E.J. Small et al., "SIMULTANEOUS ANTIANDROGEN WITHDRAWAL AND TREATMENT WITH KETOCONAZOLE AND HYDROCORTISONE IN PATIENTS WITH ADVANCED PROSTATE CARCINOMA", Cancer, 80(9), 1997, pp. 1755-1759
54. SMALL EJ; SRINIVAS S; EGAN B; MCMILLAN A; REARDEN TP
    DOXORUBICIN AND DOSE-ESCALATED CYCLOPHOSPHAMIDE WITH GRANULOCYTE-COLONY-STIMULATING FACTOR FOR THE TREATMENT OF HORMONE-RESISTANT PROSTATE-CANCER
    Journal of clinical oncology
    
    E.J. Small et al., "DOXORUBICIN AND DOSE-ESCALATED CYCLOPHOSPHAMIDE WITH GRANULOCYTE-COLONY-STIMULATING FACTOR FOR THE TREATMENT OF HORMONE-RESISTANT PROSTATE-CANCER", Journal of clinical oncology, 14(5), 1996, pp. 1617-1625
55. SMALL EJ; DAWSON NA; KANTOFF PW; VOGELZANG NJ
    CANCER AND LEUKEMIA GROUP-B TRIALS FOR ADVANCED PROSTATE-CANCER
    Seminars in oncology
    
    E.J. Small et al., "CANCER AND LEUKEMIA GROUP-B TRIALS FOR ADVANCED PROSTATE-CANCER", Seminars in oncology, 23(6), 1996, pp. 28-31
56. ROACH M; MEEHAN S; KROLL S; WEIL M; RYU J; SMALL EJ; MARGOLIS LW; PRESTI J; CARROLL PC; PHILLIPS TL
    RADIOTHERAPY FOR HIGH-GRADE CLINICALLY LOCALIZED ADENOCARCINOMA OF THE PROSTATE
    The Journal of urology
    
    M. Roach et al., "RADIOTHERAPY FOR HIGH-GRADE CLINICALLY LOCALIZED ADENOCARCINOMA OF THE PROSTATE", The Journal of urology, 156(5), 1996, pp. 1719-1723
57. SMALL EJ
    PROSTATE-SPECIFIC ANTIGEN AFTER GONADAL ANDROGEN WITHDRAWAL AND DEFERRED FLUTAMIDE TREATMENT
    The Journal of urology
    
    E.J. Small, "PROSTATE-SPECIFIC ANTIGEN AFTER GONADAL ANDROGEN WITHDRAWAL AND DEFERRED FLUTAMIDE TREATMENT", The Journal of urology, 155(5), 1996, pp. 1704-1705
58. CHER ML; BOVA GS; MOORE DH; SMALL EJ; CARROLL PR; PIN SS; EPSTEIN JI; ISAACS WB; JENSEN RH
    GENETIC ALTERATIONS IN UNTREATED METASTASES AND ANDROGEN-INDEPENDENT PROSTATE-CANCER DETECTED BY COMPARATIVE GENOMIC HYBRIDIZATION AND ALLELOTYPING
    Cancer research
    
    M.L. Cher et al., "GENETIC ALTERATIONS IN UNTREATED METASTASES AND ANDROGEN-INDEPENDENT PROSTATE-CANCER DETECTED BY COMPARATIVE GENOMIC HYBRIDIZATION AND ALLELOTYPING", Cancer research, 56(13), 1996, pp. 3091-3102
59. SMALL EJ; FIPPIN LJ; ERNEST ML; CARROLL PR
    A CARBOPLATIN-BASED REGIMEN FOR THE TREATMENT OF PATIENTS WITH ADVANCED TRANSITIONAL-CELL CARCINOMA OF THE UROTHELIUM
    Cancer
    
    E.J. Small et al., "A CARBOPLATIN-BASED REGIMEN FOR THE TREATMENT OF PATIENTS WITH ADVANCED TRANSITIONAL-CELL CARCINOMA OF THE UROTHELIUM", Cancer, 78(8), 1996, pp. 1775-1780
60. TIMMERMAN JM; NORTHFELT DW; SMALL EJ
    MALIGNANT GERM-CELL TUMORS IN MEN INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS - NATURAL-HISTORY AND RESULTS OF THERAPY
    Journal of clinical oncology
    
    J.M. Timmerman et al., "MALIGNANT GERM-CELL TUMORS IN MEN INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS - NATURAL-HISTORY AND RESULTS OF THERAPY", Journal of clinical oncology, 13(6), 1995, pp. 1391-1397
61. SMALL EJ; SRINIVAS S
    THE ANTIANDROGEN WITHDRAWAL SYNDROME - EXPERIENCE IN A LARGE COHORT OF UNSELECTED PATIENTS WITH ADVANCED PROSTRATE CANCER
    Cancer
    
    E.J. Small e S. Srinivas, "THE ANTIANDROGEN WITHDRAWAL SYNDROME - EXPERIENCE IN A LARGE COHORT OF UNSELECTED PATIENTS WITH ADVANCED PROSTRATE CANCER", Cancer, 76(8), 1995, pp. 1428-1434
62. SMALL EJ
    HORMONAL-THERAPY FOR METASTATIC PROSTATE-CANCER
    Western journal of medicine
    
    E.J. Small, "HORMONAL-THERAPY FOR METASTATIC PROSTATE-CANCER", Western journal of medicine, 160(3), 1994, pp. 253-254
63. SMALL EJ; CARROLL PR
    SERUM PSA DECLINE AFTER CASODEX WITHDRAWAL - REPLY
    Urology
    
    E.J. Small e P.R. Carroll, "SERUM PSA DECLINE AFTER CASODEX WITHDRAWAL - REPLY", Urology, 44(5), 1994, pp. 791-792
64. SMALL EJ; CARROLL PR
    PROSTATE-SPECIFIC ANTIGEN DECLINE AFTER CASODEX WITHDRAWAL - EVIDENCEFOR AN ANTIANDROGEN WITHDRAWAL SYNDROME
    Urology
    
    E.J. Small e P.R. Carroll, "PROSTATE-SPECIFIC ANTIGEN DECLINE AFTER CASODEX WITHDRAWAL - EVIDENCEFOR AN ANTIANDROGEN WITHDRAWAL SYNDROME", Urology, 43(3), 1994, pp. 408-410
65. WOLF JS; ARONSON FR; SMALL EJ; CARROLL PR
    NEPHRECTOMY FOR METASTATIC RENAL-CELL CARCINOMA - A COMPONENT OF SYSTEMIC TREATMENT REGIMENS
    Journal of surgical oncology
    
    J.S. Wolf et al., "NEPHRECTOMY FOR METASTATIC RENAL-CELL CARCINOMA - A COMPONENT OF SYSTEMIC TREATMENT REGIMENS", Journal of surgical oncology, 55(1), 1994, pp. 7-13
66. SMALL EJ; FRYE JW; WILKINSON MJ; CARROLL PR; ERNEST ML; STAGG RJ
    A PHASE I II STUDY OF ALTERNATING CONSTANT RATE INFUSION FLOXURIDINE WITH CONSTANT RATE INFUSION VINBLASTINE FOR THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA/
    Cancer
    
    E.J. Small et al., "A PHASE I II STUDY OF ALTERNATING CONSTANT RATE INFUSION FLOXURIDINE WITH CONSTANT RATE INFUSION VINBLASTINE FOR THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA/", Cancer, 73(11), 1994, pp. 2803-2807
67. SMALL EJ
    PROSTATE-CANCER - WHO TO SCREEN, AND WHAT THE RESULTS MEAN
    Geriatrics
    
    E.J. Small, "PROSTATE-CANCER - WHO TO SCREEN, AND WHAT THE RESULTS MEAN", Geriatrics, 48(12), 1993, pp. 28
68. SMALL EJ; VENOOK AP; DAMON LE
    GALLIUM-AVID THYMIC HYPERPLASIA IN AN ADULT AFTER CHEMOTHERAPY FOR HODGKINS-DISEASE
    Cancer
    
    E.J. Small et al., "GALLIUM-AVID THYMIC HYPERPLASIA IN AN ADULT AFTER CHEMOTHERAPY FOR HODGKINS-DISEASE", Cancer, 72(3), 1993, pp. 905-908
69. WILKINSON MJ; FRYE JW; SMALL EJ; VENOOK AP; CARROLL PR; ERNEST ML; STAGG RJ
    A PHASE-II STUDY OF CONSTANT-INFUSION FLOXURIDINE FOR THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA
    Cancer
    
    M.J. Wilkinson et al., "A PHASE-II STUDY OF CONSTANT-INFUSION FLOXURIDINE FOR THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA", Cancer, 71(11), 1993, pp. 3601-3604